Clinical Trial Update: Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib with rituximab for relapsed/refractory DLBCL with MYD88 and CD79A/B mutations after at least two prior the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: DLBCL, MYD88 Gene Mutation | Phase 2 | Status: UNKNOWN